A Markov model to evaluate cost-effectiveness of the PARP inhibitor, olaparib, for fourth-line treatment of recurrent ovarian cancer

Journal article

Peer reviewed

Juliet Elizabeth Wolford, Jiaru Bai, Ramez Hassef Eskander, Robin Keller, Lindsey Minion, John K. Chan, Bradley J. Monk and Krishnansu Sujata Tewari

Journal of clinical oncology, Vol.34(15_suppl), pp.5563-5563

05/20/2016

Abstract

Abstract only

8 Record Views

Title: A Markov model to evaluate cost-effectiveness of the PARP inhibitor, olaparib, for fourth-line treatment of recurrent ovarian cancer
Creators: Juliet Elizabeth Wolford - UC Irvine Health
Jiaru Bai - UC Irvine Health
Ramez Hassef Eskander - University of California, Irvine
Robin Keller - University of California, Irvine
Lindsey Minion - St. Joseph's Hospital and Medical Center
John K. Chan - Palo Alto Medical Foundation
Bradley J. Monk - Dignity Health
Krishnansu Sujata Tewari - University of California, Irvine Medical Center
Publication Details: Journal of clinical oncology, Vol.34(15_suppl), pp.5563-5563
Identifiers: 991005969133702656
Academic Unit: Obstetrics & Gynecology
Language: English
Resource Type: Journal article